Immune checkpoint inhibitors (ICIs), such as monoclonal antibodies directed against PD-1 and its ligand programmed death-ligand 1 (PD-L1) are used to block the inhibition of the host cytotoxic T-cell activity against a tumor (Figure 1). This evidence concerns the gene CD274 and neoplasm.